Crédit Industriel et Commercial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Crédit Industriel et Commercial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.89M	Sell	33,013 -7,000	-17%	-$383K	0.12%	156
2026 Q1	$2.26M	Hold	40,013	–	–	0.18%	137
2025 Q4	$2.38M	Hold	40,013	–	–	0.18%	125
2025 Q3	$2.17M	Hold	40,013	–	–	0.18%	128
2025 Q2	$2.2M	Buy	40,013 +5,000	+14%	+$294K	0.19%	132
2025 Q1	$2.48M	Hold	35,013	–	–	0.26%	103
2024 Q4	$2.3M	Buy	+35,013	New	+$2.35M	0.3%	94

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Crédit Industriel et Commercial's BMRN Position: Q2 2026 in Review

Crédit Industriel et Commercial reduced its BioMarin Pharmaceuticals (BMRN) stake by 17% in Q2 2026, selling an estimated $383K and leaving 33,013 shares worth $1.89M. The position accounts for 0.12% of the portfolio, ranked #156.

Crédit Industriel et Commercial first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.48M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Crédit Industriel et Commercial held 33,013 shares of BioMarin Pharmaceuticals worth $1.89M as of Q2 2026.
Crédit Industriel et Commercial sold 7,000 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $383K.
BioMarin Pharmaceuticals made up 0.12% of Crédit Industriel et Commercial's portfolio in Q2 2026, its #156 holding.
Crédit Industriel et Commercial first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Crédit Industriel et Commercial's BioMarin Pharmaceuticals position peaked at $2.48M in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Crédit Industriel et Commercial's 13F filing for Q2 2026, filed 24 Jul 2026.